upleganan   Click here for help

GtoPdb Ligand ID: 12797

Synonyms: compound 44 [PMID: 31525992] | EVER206 | SPR206
Compound class: Synthetic organic
Comment: Upleganan (SPR206) is a polymyxin antibacterial with activity against multi-drug resistant (MDR) Gram-negative species, together with lower nephrotoxicity than polymyxin B [1].
2D Structure
Click here for help

2D Structure

An image of the ligand's 2D structure. For small molecules with SMILES these are drawn using the NCI/CADD Chemical Identifier Resolver. Click on the image to access the chemical structure search tool with the ligand pre-loaded in the structure editor. For other types of ligands, e.g. longer nucleotides and peptides, a manually drawn representation of the molecule may be provided.

✖
Click here for structure editor
Physico-chemical Properties
Click here for help

Physico-chemical Properties

Calculated molecular properties are available for small molecules and natural products (not peptides). Properties were generated using the CDK toolkit. All properties were selected to enable the prediction of the Lipinski Rule-of-Five profile or ‘druglikeness’ for each ligand. For more info on each category see the help pages.

✖
Hydrogen bond acceptors 27
Hydrogen bond donors 17
Rotatable bonds 25
Topological polar surface area 461.56
Molecular weight 1144.76
XLogP -1.47
No. Lipinski's rules broken 4
SMILES / InChI / InChIKey
Click here for help

SMILES / InChI / InChIKey

SMILES (Simplified Molecular Input Line Entry Specification) A specification for unambiguously describing the structure of chemical molecules using short ASCII strings. Canonical SMILES specify a unique representation of the 2D structure without chiral or isotopic specifications. Isomeric SMILES include chiral specification and isotopes.

Standard InChI (IUPAC International Chemical Identifier) and InChIKey InChI is a non-proprietary, standard, textual identifier for chemical substances designed to facilitate linking of information and database searching. An InChIKey is a simplified version of a full InChI, designed for easier web searching.

✖
Canonical SMILES CC(C)C[C@H]1C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@]([H])([C@@H](C)O)C(=O)NCC[C@@H](C(=O)N[C@@H](CCN)C(=O)N[C@H](CC2=CC=CC=C2)C(=O)N1)NC(=O)[C@H](CN)NC(=O)[C@H]([C@@H](C)O)NC(=O)C[C@H](CN)C3=CC=CC(=C3)Cl
Isomeric SMILES C([C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCN)C(=O)N[C@@H](CCN)C(=O)N[C@@]([C@@H](C)O)(C(=O)NCC[C@H](NC([C@@H](NC([C@@H](NC(C[C@H](CN)C2=CC(Cl)=CC=C2)=O)[C@@H](C)O)=O)CN)=O)C(=O)N[C@@H](CCN)C(=O)N1)[H])C3=CC=CC=C3
InChI InChI=1S/C52H82ClN15O12/c1-27(2)21-38-48(76)62-34(13-17-54)44(72)61-36(15-19-56)47(75)68-42(28(3)69)51(79)59-20-16-37(46(74)60-35(14-18-55)45(73)65-39(49(77)64-38)22-30-9-6-5-7-10-30)63-50(78)40(26-58)66-52(80)43(29(4)70)67-41(71)24-32(25-57)31-11-8-12-33(53)23-31/h5-12,23,27-29,32,34-40,42-43,69-70H,13-22,24-26,54-58H2,1-4H3,(H,59,79)(H,60,74)(H,61,72)(H,62,76)(H,63,78)(H,64,77)(H,65,73)(H,66,80)(H,67,71)(H,68,75)/t28-,29-,32-,34+,35+,36+,37+,38+,39-,40+,42+,43+/m1/s1
InChI Key VAZVBVUQVUHPMS-DFEDBOKMSA-N
No information available.
Summary of Clinical Use Click here for help
Upleganan is being developed by Spero Therapeutics as an intravenous administered treatment for hospital-acquired and ventilator-associated bacterial pneumonia caused by MDR Gram-negative pathogens. Three Phase 1 trials have been completed (NCT03792308, NCT04865393, NCT04868292) with the drug generally well tolerated in healthy subjects [2-3].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04865393 Phase 1 Study of PK and Safety of SPR206 in Subjects With Various Degrees Of Renal Function Phase 1 Interventional Spero Therapeutics
NCT04868292 Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers Phase 1 Interventional Spero Therapeutics 3
NCT03792308 A First in Human Study of the Safety and Tolerability of Single and Multiple Doses of SPR206 in Healthy Volunteers Phase 1 Interventional Spero Therapeutics The drug was found to be generally safe and well tolerated. The incidence of adverse events increased with dose but most were of mild severity. No evidence of nephrotoxicity was observed over 14 days, using a dosing regimen that should exceed requirements for clinical efficacy. 2